An interventional study of Whole-Body Photobiomodulation (PBM) (Active PBM) and Sham PBM in Athletic Performance, Muscle Fatigue and Muscle Strength, sponsored by Universidade Federal de Sao Carlos. Recruiting at 1 site in Brazil. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Universidade Federal de Sao Carlos · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Fatigue with a site in Brazil — 9 open to participants now, 13 under way, 2 of them phase 3. Fatigue · Brazil.
Among the 57 studies in Fatigue with a site in Brazil, this one is the 46th largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2025, is one of 44 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 53rd registered.
2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.
Browse Fatigue studies →9 of the 57 studies in Fatigue with a site in Brazil are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Brazil, United States, Australia and 17 more countries
Ages 18+
Federal University of Rio Grande do Sul · Sites in Brazil
Ages 18–45 · Healthy volunteers
Pfizer · Sites in Brazil, United States, Australia and 18 more countries
Ages 18+
University of Nove de Julho · Sites in Brazil
Ages 18+ · Healthy volunteers
Universidade Federal de Pernambuco · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 242 Fatigue studies recruiting now, 113 (47%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 35 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 3 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 54 across 1,762 interventional studies indexed under Fatigue.
Median enrollment 40 across the 54 interventional studies, 50 across the 3 observational. Of the 32 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 57 have an industry lead sponsor. The 10 most frequent:
Universidade Federal de Sao Carlos is the lead sponsor of 86 studies on the registry; 8 are open to participants now.
Universidade Federal de Sao Carlos has 2 studies filed under Fatigue — fewer than ten, so there is no comparison to draw.
1 of the studies in Fatigue with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06933446Luis Gustavo Lizi JorgeEffect of Myofascial Release on Post-Exercise Recovery in Water Polo Athletes | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 57 studies in Fatigue with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the effects of whole-body photobiomodulation on professional soccer players during a state championship. The primary question is whether photobiomodulation improves recovery, reduces muscle fatigue, and enhances performance compared to standard training without photobiomodulation.
Detailed Description:
This randomized, controlled clinical trial aims to evaluate the effects of whole-body photobiomodulation (PBM) on recovery and performance in professional soccer players during a state championship.
The intervention will be performed twice weekly on non-consecutive days for 8 weeks, in combination with each athlete's standard training routine. Participants will be allocated to either an active PBM group or a sham PBM group, both following identical procedures to maintain blinding.
Throughout the study, participants will complete scheduled assessments at baseline, during, and after the 8-week period to monitor performance, muscle soreness, and hematological responses. Data will be analyzed using appropriate statistical tests, with a significance level of 5% (two-tailed).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Whole-body PBM delivered with a Joovv Elite System (6 LED panels; 660±10 nm red and 850±10 nm near-infrared; total panel area ≈12,193 cm²). Athlete stands \~20 cm from panels, wearing eye protection. Two exposures per session: 450 s anterior + 450 s posterior (total 15 min). Measured average irradiance ≈81.62 mW/cm² and energy density per region ≈25.71 J/cm² at 20 cm. Two sessions/week on non-consecutive days for 8 weeks, after routine training.
Radiation: Whole-Body Photobiomodulation (PBM) (Active PBM)
Identical setup and schedule, but with therapeutic light disabled (placebo light only). Eye protection and blinding procedures identical to active PBM.
Radiation: Sham PBM
This intervention consists of whole-body photobiomodulation delivered using a full-body PBM device. Sessions are performed twice weekly on non-consecutive days for 8 weeks, coinciding with the athletes' standard training. The device emits therapeutic light at specified wavelengths and power, targeting the entire body. The protocol is standardized according to prior research, ensuring consistent exposure for all participants in the active arm. The intervention aims to improve muscle performance and recovery while reducing delayed onset muscle soreness (DOMS).
Intervention Description (Sham PBM): Participants receive a sham photobiomodulation intervention using the same device and schedule, but without emission of therapeutic light. The procedure mimics the active intervention to maintain blinding while allowing comparison of outcomes, including muscle performance, DOMS, and blood markers.
Delayed Onset Muscle Soreness (DOMS)
Pain intensity measured using the Numeric Rating Scale (NRS; 0-10 points; higher scores = worse pain) during a maximal voluntary knee-extension contraction in sitting. Pain location/extent captured with a standardized pain drawing (exploratory). Primary analysis uses NRS.
Time frame: Baseline (T1), weekly (T2, weeks 1-8), and end of week 8 (T3).
Knee Extensor Strength (Hand-Held Dynamometry)
Peak force of dominant-leg knee extensors measured with a handheld dynamometer in standardized seated position; mean of two MVC attempts used for analysis.
Time frame: Baseline (T1), weekly (T2, weeks 1-8), end of week 8 (T3)
Squat Jump (SJ) Height
Vertical jump height (cm) from Squat Jump (SJ) with hands on hips; mean of two trials; flight-time method on contact device.
Time frame: Baseline (T1), weekly (T2, weeks 1-8), end of week 8 (T3) Unit: cm
Countermovement Jump (CMJ) Height
Vertical jump height (cm) from Countermovement Jump (CMJ) with hands on hips; mean of two trials; flight-time method on contact device.
Time frame: Baseline (T1), weekly (T2, weeks 1-8), end of week 8 (T3)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — At this time, the plan for sharing individual participant data (IPD) has not been determined. Decisions regarding data sharing will be made after study completion, considering participant privacy, ethical approvals, and applicable institutional policies.
Started Sep 2025 (actual). Primary completion is estimated for Aug 2026, 11 months after the start.
Of 937 non-industry interventional studies with no phase under Fatigue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 11 months is close to that.
Counting every sponsor, half of 990 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidade Federal de Sao Carlos